Upfront docetaxel for castration-sensitive metastatic prostate cancer in an ethnically diverse inner-city population.

被引：0
|
作者：
Pathak, Surabhi
Thekkekara, Romy Jose
Ahmed, Ahmed T.
Yadav, Udit
Mullane, Michael Russell
Batra, Kumar Kunnal
Lad, Thomas E.
Psutka, Sarah P.
机构：
[1] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA
[2] Cook Cty Hlth & Hosp Syst, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e17038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17038
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer
    Briones, Juan
    Khan, Maira
    Sidhu, Amanjot K.
    Zhang, Liying
    Smoragiewicz, Martin
    Emmenegger, Urban
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [32] Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study
    Tanaka, Toshikazu
    Hatakeyama, Shingo
    Noro, Daisuke
    Togashi, Kyo
    Yoneyama, Takahiro
    Ohyama, Chikara
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (05) : 476 - 478
  • [33] Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study
    Hatakeyama, Shingo
    Narita, Shintaro
    Takahashi, Masahiro
    Sakurai, Toshihiko
    Kawamura, Sadafumi
    Hoshi, Senji
    Ishida, Masanori
    Kawaguchi, Toshiaki
    Ishidoya, Shigeto
    Shimoda, Jiro
    Sato, Hiromi
    Hamano, Itsuto
    Okamoto, Teppei
    Mitsuzuka, Koji
    Ito, Akihiro
    Tsuchiya, Norihiko
    Arai, Yoichi
    Habuchi, Tomonori
    Ohyama, Chikara
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (07) : 610 - 617
  • [34] Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.
    Chandran, Elias
    Goswami, Meghali
    Donahue, Renee Nicole
    Atiq, Mohammad O.
    Karzai, Fatima
    Bilusic, Marijo
    Marte, Jennifer L.
    Arlen, Philip M.
    Cordes, Lisa M.
    Owens, Helen
    Hausler, Megan
    Hankin, Amy
    Williams, Monique
    Dahut, William L.
    Figg, William Douglas
    Schlom, Jeffrey
    Gulley, James L.
    Madan, Ravi Amrit
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [35] Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2018, 199 (01): : 26 - 28
  • [36] First-line Therapy for Metastatic Castration-sensitive Prostate Cancer
    Lau, Y. H.
    Wan, L. Y.
    Lam, M. H. C.
    HONG KONG JOURNAL OF RADIOLOGY, 2022, 25 (03): : 244 - 245
  • [37] A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer
    Kwon, Daniel Hyuck-Min
    Friedlander, Terence
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [38] The cost impact of disease progression to metastatic castration-sensitive prostate cancer
    Quoc-Dien Trinh
    Chaves, Leonardo Passos
    Feng, Qi
    Zhu, Julia
    Sandin, Rickard
    Abbott, Thomas
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (05): : 544 - 554
  • [39] Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer
    Dandapani, Savita V.
    Wong, Jeffrey
    Twardowski, Przemyslaw
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (07) : 490 - 496
  • [40] Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer
    Grisay, Guillaume
    Lavaud, Pernelle
    Fizazi, Karim
    CURRENT ONCOLOGY REPORTS, 2024, 26 (05) : 488 - 495
12345